Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
US-12180196-B2 · Dec 31, 2024 · US
US9388159B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9388159-B2 |
| Application number | US-201414318234-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 27, 2014 |
| Priority date | Mar 27, 2006 |
| Publication date | Jul 12, 2016 |
| Grant date | Jul 12, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
This invention provides for compounds of the Formula II: wherein A, B, Het, R 1 , R 2 and R 3 are as described herein. These compounds are androgen receptor modulators useful for the treatment of androgen receptor-associated conditions.
Opening claim text (preview).
We claim: 1. A compound having the Formula II: wherein Het is a heterocyclic unit of 6 atoms comprising 1 or 2 heteroatoms independently selected from the group consisting of nitrogen, oxygen, or sulfur; 0 or 1 double-bonded substituent on the heterocyclic unit selected from the group consisting of oxygen and sulfur; and 3 to 4 single-bonded substituents on the heterocyclic unit independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, arylalkenyl, arylalkynyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogen, CN, NO 2 , OR 11 , SR 11 , NR 11 R 12 , NH(CO)OR 11 , NH(CO)NR 11 R 12 , NR 12 (CO)R 11 , O(CO)R 11 , O(CO)OR 11 , O(CS)R 11 , NR 12 (CS)R 11 , NH(CS)NR 11 R 12 , NR 12 (CS)OR 11 , wherein two of said single-bonded substituents may be connected together with the atoms to which they are bonded to form a cycle, which is aryl, substituted aryl, heterocyclic aromatic or non-aromatic, substituted heterocyclic aromatic or non-aromatic, cycloalkyl, or substituted cycloalkyl; A is sulfur and B is oxygen; R 11 and R 12 are independently selected from hydrogen, alkyl, substituted alkyl, alkenyl or substituted alkenyl, alkynyl or substituted alkynyl, aryl, substituted aryl, arylalkyl, arylalkenyl, arylalkynyl, heterocyclic aromatic or non-aromatic, or substituted heterocyclic aromatic or non-aromatic, wherein R 11 and R 12 , both on the same single bonded substituent, can be connected together with the atoms to which they are bonded to form a cycle, which can be heterocyclic aromatic or non-aromatic, or substituted heterocyclic aromatic; R 1 is selected from aryl and substituted aryl; R 2 and R 3 together with the carbon to which they are linked, form a cycloalkyl or substituted cycloalkyl; wherein each substituted alkyl is substituted with one or more groups selected from hydroxy, bromo, fluoro, chloro, iodo, mercapto, cyano, alkylthio, heterocyclyl, aryl, heteroaryl, carboxy, carbalkoyl, alkyl, alkenyl, nitro, amino, alkoxy, or amido; wherein each substituted cycloalkyl, substituted alkenyl, substituted alkynyl, or substituted heterocyclic non-aromatic is substituted with one or more groups selected from halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, alkylthio, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, heteroaryl, carboxy, carbalkoyl, alkenyl, or amido; wherein each substituted arylalkyl, arylalkenyl, or arylalkynyl is substituted on the aryl portion with one or more groups selected from halogen, alkyl, alkoxy, hydroxyl, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, alkylthio, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, heteroaryl, carboxyl, carbalkoyl, alkenyl, or amido; wherein each substituted aryl or substituted aromatic is substituted with one or more groups selected from halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, trifluoromethyl, trifluoromethoxy, alkynyl, cycloalkyl, cycloalkylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, alkoxycarbonyl, arylcarbonyl, arylalkenyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, hydroxy, nitro, cyano, carbamoyl, alkylcarbamoyl, amidified carboxy, amidified carboxyalkyl, alkyl amidified carboxyalkyl, thiol, alkylthio, arylthio, heteroarylthio, arylthioalkyl, alkoxyarylthio, alkylcarbonyl, arylcarbonyl, alkylaminocarbonyl, arylaminocarbonyl, alkoxycarbonyl, aminocarbonyl, alkylcarbonyloxy, arylcarbonyloxy, alkylcarbonylamino, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino, arylsulfonaminocarbonyl, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, carboxy, carbalkoyl, alkoxy, amido, amino, or amino substituted with one or two substituents selected from the group consisting of alkyl, aryl, heteroaryl, arylalkyl, aryloxy, aryloxyalkyl, arylalkoxy, arylcarbonyl, arylalkenyl, arylalkynyl, aminocarbonylaryl, arylthio, arylsulfinyl, arylazo, heteroarylalkyl, heteroarylalkenyl, heteroarylheteroaryl, heteroaryloxy, heteroarylthio, arylthioalkyl, alkoxyarylthio, arylaminocarbonyl, arylcarbonyloxy, arylcarbonylamino, arylsulfinyl, arylsulfinylalkyl, arylsulfonylamino, and arylsulfonaminocarbonyl; and wherein substituted heteroaryl or substituted heterocyclic aromatic is substituted with one, two, three or four groups selected from halogen, alkyl, alkoxy, hydroxy, aryl, aryloxy, arylalkyl, cycloalkyl, alkylamido, alkanoylamino, oxo, acyl, arylcarbonylamino, amino, nitro, cyano, thiol, alkylthio, bromo, fluoro, chloro, iodo, mercapto, heterocyclyl, heteroaryl, carboxy, carbalkoyl, alkenyl, or amido. 2. The compound of claim 1 , wherein R 1 is selected from the group consisting of phenyl and substituted phenyl. 3. The compound of claim 2 , wherein phenyl is substituted with fluoro. 4. The compound of claim 2 , wherein phenyl is substituted with methyl. 5. The compound of claim 2 , wherein phenyl is substituted with —C(O)NHCH 3 . 6. The compound of claim 1 , wherein Het is selected from the group consisting of wherein R 4 , R 5 , R 6 , and R 7 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, aryl alkenyl, arylalkynyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogen, CN, NO 2 , OR 11 , SR 11 , NR 11 R 12 , NH(CO)OR 11 , NH(CO)NR 11 R 12 , NR 12 (CO)R 11 , O(CO)R 11 , O(CO)OR 11 , O(CS)R 11 , NR 12 (CS)R 11 , NH(CS)NR 11 R 12 , NR 12 (CS)OR 11 ; or any of R 4 , R 5 , R 6 , and R 7 can be connected to any of R 4 , R 5 , R 6 , and R 7 to form a cycle which is aryl, substituted aryl, heterocyclic aromatic or non-aromatic, substituted heterocyclic aromatic or non-aromatic, cycloalkyl, or substituted cycloalkyl. 7. The compound of claim 6 , wherein Het is selected from the group consisting of 8. The compound of claim 6 , wherein R 4 is selected from the group consisting of CN and NO 2 ; R 5 is selected from the group consisting of halogenated alkyl, halogenated alkenyl, halogenated alkynyl, and halogen; and R 6 , and R 7 are independently selected from the group consisting of hydrogen, alkyl, and halogen. 9. The compound of claim 6 , wherein Het is selected from the group consisting of 10. The compound of claim 1 , wherein R 2 and R 3 , together with the carbon to which they are linked, form a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. 11. The compound of claim 1 , wherein R 2 and R 3 , together with the carbon to which they are linked, form a cycloalkyl. 12. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or adjuvant. 13. The pharmaceutical composition of claim 12 , formulated to deliver a therapeutic
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antineoplastic agents · CPC title
for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis · CPC title
of the prostate · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.